FDA Investigating Clarinex Approval
- Share via
The Food and Drug Administration is probing approval of Schering-Plough Corp.’s allergy drug Clarinex because an outside consultant may have had a conflict of interest, said FDAWebview, an Internet publication on the drug industry.
The private firm Lachman Consultant Services inspected the plant that makes Clarinex, the report said. The same firm was an auditor for the Kenilworth, N.J.-based drug maker, according to the report.
Schering-Plough shares fell 70 cents to $29.94 on the NYSE.
Neither Lachman, Schering-Plough nor FDA officials returned calls seeking comment.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
